NRx Pharmaceuticals’ (NRXP) Buy Rating Reaffirmed at BTIG Research

BTIG Research restated their buy rating on shares of NRx Pharmaceuticals (NASDAQ:NRXP) in a research report report published on Tuesday,Benzinga reports. The firm currently has a $25.00 price target on the stock.

Other analysts have also issued reports about the company. Ascendiant Capital Markets reiterated a “buy” rating and issued a $48.00 price objective (up from $47.00) on shares of NRx Pharmaceuticals in a research report on Friday, January 2nd. HC Wainwright boosted their price target on shares of NRx Pharmaceuticals from $40.00 to $45.00 and gave the stock a “buy” rating in a research note on Tuesday, March 3rd. Zacks Research upgraded shares of NRx Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Monday, March 2nd. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of NRx Pharmaceuticals in a research note on Monday, December 29th. Finally, D. Boral Capital reaffirmed a “buy” rating and set a $34.00 target price on shares of NRx Pharmaceuticals in a report on Monday, March 16th. Four analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, NRx Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $38.00.

NRx Pharmaceuticals Price Performance

NRXP opened at $2.13 on Tuesday. The stock has a market capitalization of $67.88 million, a P/E ratio of -1.53 and a beta of 1.97. The company’s 50 day simple moving average is $1.94 and its 200-day simple moving average is $2.44. NRx Pharmaceuticals has a one year low of $1.58 and a one year high of $3.84.

NRx Pharmaceuticals (NASDAQ:NRXP) last posted its quarterly earnings data on Monday, March 23rd. The company reported $0.19 earnings per share for the quarter, topping the consensus estimate of ($0.09) by $0.28. The company had revenue of $0.98 million during the quarter, compared to the consensus estimate of $7.53 million. As a group, analysts anticipate that NRx Pharmaceuticals will post -1.75 EPS for the current year.

Institutional Trading of NRx Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Ethos Financial Group LLC acquired a new stake in shares of NRx Pharmaceuticals in the 3rd quarter valued at approximately $39,000. Sjbenen Advisory LLC acquired a new position in NRx Pharmaceuticals during the fourth quarter valued at approximately $41,000. One Wealth Management Investment & Advisory Services LLC grew its holdings in NRx Pharmaceuticals by 86.1% during the third quarter. One Wealth Management Investment & Advisory Services LLC now owns 27,991 shares of the company’s stock valued at $92,000 after purchasing an additional 12,950 shares during the period. Global Retirement Partners LLC bought a new stake in NRx Pharmaceuticals in the fourth quarter valued at approximately $107,000. Finally, Two Sigma Investments LP increased its stake in NRx Pharmaceuticals by 66.4% in the third quarter. Two Sigma Investments LP now owns 52,332 shares of the company’s stock valued at $173,000 after purchasing an additional 20,880 shares in the last quarter. 4.27% of the stock is owned by institutional investors.

Key Headlines Impacting NRx Pharmaceuticals

Here are the key news stories impacting NRx Pharmaceuticals this week:

• Positive Sentiment: D. Boral Capital reaffirmed a “buy” and set a $34.00 price target — a very large upside projection that can attract momentum buyers. Benzinga Article
• Positive Sentiment: BTIG Research reaffirmed its “buy” and set a $25.00 price target, another high-profile bullish endorsement likely supporting the rally. Benzinga Article
• Positive Sentiment: Q4 EPS of $0.19 topped consensus (loss of $0.09), a clear earnings beat that likely improved sentiment despite underlying revenue weakness. Press Release
• Neutral Sentiment: Company reported full-year 2025 results and says it ended the year with $7.8M cash and expects adequate resources to operate through 2026 given current revenue and ATM trends — supportive for near-term runway but not a long-term funding solution. GlobeNewswire Release
• Neutral Sentiment: Investor/analyst call prepared remarks/transcript available for review — useful for assessing management tone and guidance but not an immediate directional catalyst by itself. Seeking Alpha Transcript
• Negative Sentiment: Revenue for the quarter was $0.98M, well below analyst expectations (~$7.5M), which is a meaningful operational miss that could concern fundamental investors if not explained by one-time items. Zacks Article
• Neutral Sentiment: Several short-interest notices show anomalous/zero reported short positions (and NaN changes) for March — the data appears inconsistent/placeholder and does not provide a clear short-squeeze signal at this time.

NRx Pharmaceuticals Company Profile

NRx Pharmaceuticals, Inc is a clinical-stage specialty biopharmaceutical company focused on the development and repurposing of small-molecule therapeutics for central nervous system and rare disease indications. The company’s research strategy centers on advancing compounds with established safety profiles into new neurological and inflammatory conditions, leveraging translational science and biomarker-driven trial design to accelerate clinical development. NRx’s pipeline includes Ifenprodil, an NMDA receptor antagonist in investigation for acute respiratory distress syndrome and inflammatory muscle disorders, as well as investigational formulations targeting depressive and cognitive disorders.

Since securing global rights to its lead assets, NRx has initiated multiple proof-of-concept studies in the United States and Europe, collaborating with academic institutions and clinical research organizations to evaluate safety and efficacy across a range of indications.